1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with an HR 0.62 (significant). 2. Adverse events grade 3 or higher occurred in 18.6% of the pembrolizumab group vs 1.2% in the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Adjuvant therapy for localized
1. The overall survival at 48 months was 91.2% in the pembrolizumab group vs 86.0% in the placebo group, with an HR 0.62 (significant). 2. Adverse events grade 3 or higher occurred in 18.6% of the pembrolizumab group vs 1.2% in the placebo group. Evidence Rating Level: 1 (Excellent) Study Rundown: Adjuvant therapy for localized
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.
OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ASCO Annual Meeting. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across hematologic oncology during the conference.